Bevacizumab

Adult: In combination with interferon alfa-2a: 10 mg/kg once every 2 weeks. Administer the 1st infusion over 90 minutes; if tolerated, administer the 2nd infusion over 60 minutes, and if this is well-tolerated then subsequent doses may be given over 30 minutes. Dosing interruption or discontinuation may be required according to individual safety or tolerability. Treatment and dosing recommendations may vary among individual products and between countries. Refer to detailed product or local treatment guidelines.

Adult: As 1st-line treatment in patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer: 7.5 mg/kg or 15 mg/kg once every 3 weeks (in addition to platinum-based chemotherapy) for up to 6 cycles followed by bevacizumab as a single agent until disease progression. Administer the 1st infusion over 90 minutes; if tolerated, administer the 2nd infusion over 60 minutes, and if this is well-tolerated then subsequent doses may be given over 30 minutes. Dosing interruption or discontinuation may be required according to individual safety or tolerability. Treatment and dosing recommendations may vary among individual products and between countries. Refer to detailed product or local treatment guidelines.

Adult: In patients with persistent, recurrent, or metastatic cervical cancer; in combination with paclitaxel and cisplatin or paclitaxel and topotecan: 15 mg/kg once every 3 weeks. Administer the 1st infusion over 90 minutes; if tolerated, administer the 2nd infusion over 60 minutes, and if this is well-tolerated then subsequent doses may be given over 30 minutes. Dosing interruption or discontinuation may be required according to individual safety or tolerability. Treatment and dosing recommendations may vary among individual products and between countries. Refer to detailed product or local treatment guidelines.

Adult: As 1st- or 2nd-line treatment in combination with fluorouracil-based chemotherapy: 5 mg/kg or 10 mg/kg once every 2 weeks; doses depend on the combination of drugs used in the regimen. As 2nd-line treatment in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy after progression on a 1st-line treatment containing bevacizumab: 5 mg/kg once every 2 weeks or 7.5 mg/kg once every 3 weeks; doses depend on the combination of drugs used in the regimen. Administer the 1st infusion over 90 minutes; if tolerated, administer the 2nd infusion over 60 minutes, and if this is well-tolerated then subsequent doses may be given over 30 minutes. Dosing interruption or discontinuation may be required according to individual safety or tolerability. Treatment and dosing recommendations may vary among individual products and between countries. Refer to detailed product or local treatment guidelines.

Adult: 10 mg/kg once every 2 weeks. Administer the 1st infusion over 90 minutes; if tolerated, administer the 2nd infusion over 60 minutes, and if this is well-tolerated then subsequent doses may be given over 30 minutes. Dosing interruption or discontinuation may be required according to individual safety or tolerability. Treatment and dosing recommendations may vary among individual products and between countries. Refer to detailed product or local treatment guidelines.

Adult: In combination with atezolizumab in patients who have not received prior systemic therapy: 15 mg/kg once every 3 weeks. Administer the 1st infusion over 90 minutes; if tolerated, administer the 2nd infusion over 60 minutes, and if this is well-tolerated then subsequent doses may be given over 30 minutes. Continue therapy until disease progression or unacceptable toxicity occurs. Dosing interruption or discontinuation may be required according to individual safety or tolerability. Treatment and dosing recommendations may vary among individual products and between countries. Refer to detailed product or local treatment guidelines.

Adult: As 1st-line treatment in combination with paclitaxel: 10 mg/kg once every 2 weeks or 15 mg/kg once every 3 weeks. Administer the 1st infusion over 90 minutes; if tolerated, administer the 2nd infusion over 60 minutes, and if this is well-tolerated then subsequent doses may be given over 30 minutes. Continue therapy until disease progression or unacceptable toxicity occurs. Dosing interruption or discontinuation may be required according to individual safety or tolerability. Treatment and dosing recommendations may vary among individual products and between countries. Refer to detailed product or local treatment guidelines.

Adult: In patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection: 15 mg/kg once every 3 weeks (in combination with carboplatin and paclitaxel) for up to 6 cycles, followed by bevacizumab 15 mg/kg once every 3 weeks as a single agent for 15 months or until disease progression, whichever occurs earlier. In patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens: 10 mg/kg once every 2 weeks (in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan) or 15 mg/kg every 3 weeks (in combination with topotecan). Continue therapy until disease progression. In patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: 15 mg/kg once every 3 weeks (in combination with carboplatin and paclitaxel) for 6-8 cycles, followed by bevacizumab 15 mg/kg once every 3 weeks as a single agent until disease progression. Alternatively, 15 mg/kg every 3 weeks (in combination with carboplatin and gemcitabine) for 6-10 cycles, followed by bevacizumab 15 mg/kg every 3 weeks as a single agent until disease progression. All doses are administered via IV infusion initially over 90 minutes; if tolerated, administer the 2nd infusion over 60 minutes, and if this is well-tolerated then subsequent doses may be given over 30 minutes. Dosing interruption or discontinuation may be required according to individual safety or tolerability. Treatment and dosing recommendations may vary among individual products and between countries. Refer to detailed product or local treatment guidelines.